Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	¥434.00	-0.23%	7,200
17/09/26	¥435.00	-0.23%	5,600
16/09/26	¥436.00	+0.46%	15,000
15/09/26	¥434.00	+2.12%	8,300

Delayed Quote Japan Exchange

More quotes

Market Closed - Japan Exchange 10:30:00 18/09/2026 +04			5-day change	1st Jan Change
434.00 ^JPY	-0.23%		0.00%	-9.58%

08-05	Veritas In Silico Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-04	Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug	MT

Market Cap	2.82B 17.78M 15.61M 14.67M 13.41M 25.06M 1.7B 25.25M 176M 68.31M 868M 66.77M 65.31M	P/E 2024	-23.8x	P/E 2025	-7.32x
Enterprise Value	990M 6.25M 5.49M 5.16M 4.72M 8.81M 599M 8.88M 61.97M 24.02M 305M 23.48M 22.97M	EV / Sales 2024	18.2x	EV / Sales 2025	14.1x
Free-Float	45.01%	Yield 2024 *	-	Yield 2025	-

08-05	Veritas In Silico Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-04	Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug	MT
05-11	SpiroChem AG and Veritas in Silico Inc. Enter Joint Research Agreement to Initiate Discovery of Next Generation mRNA Binding Chemical Matter	CI
04-13	Veritas In Silico and Takeda Mutually Terminate mRNA-Targeted Drug Research Collaboration	MT
04-13	Veritas in Silico Inc. Terminates Collaborative Drug Discovery Research with Takeda Pharmaceutical Company Limited	CI
02-12	Veritas in Silico Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026	CI
02-12	Veritas In Silico Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-26	SpiroChem AG and Veritas In Silico Inc. Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter	CI
01-19	The Jikei University School of Medicine and Veritas In Silico Inc. Announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting Amyotrophic Lateral Sclerosis	CI
01-19	Japan Shares Start Week in Red as Trump Threatens More Tariffs on Europe	MT
01-19	Veritas In Silico, Jikei University Patent ALS Nucleic Acid Therapy	MT
12-22	Veritas In Silico Files Patent for mRNA-Targeted Kidney Injury Drug	MT
12-15	Veritas in Silico, Inc. Announces Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio"	CI

1 day	-0.23%
Current month	-2.69%
1 month	-3.12%
3 months	+5.60%
6 months	-8.63%
Current year	-9.58%

Veritas In Silico Inc. Stock

Stocks

130A

JP3155340007

Biotechnology & Medical Research

Valuation: Veritas In Silico Inc.

Chart: Veritas In Silico Inc.

Latest news: Veritas In Silico Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Veritas In Silico Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	432	440
1 month	411	464
Current year	390	586
1 year	390	793
3 years	390	3,475
5 years	390	3,475
10 years	390	3,475

Manager	Title	Age	Since
Shingo Nakamura CEO	Chief Executive Officer	54	17/11/2016
Hiroaki Hagiwara DFI	Director of Finance/CFO	57	01/01/2022
Isao Koda PRN	Corporate Officer/Principal	69	01/12/2018

Director	Title	Age	Since
Shingo Nakamura BRD	Director/Board Member	54	17/11/2016
Kinichiro Kominami BRD	Director/Board Member	59	01/08/2019
Hiroaki Hagiwara BRD	Director/Board Member	57	01/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VERITAS IN SILICO INC.	-0.23%	0.00%	-39.64%	-	17.89M
LONZA GROUP AG	-0.18%	+4.35%	+4.23%	+30.02%	47.86B
IQVIA HOLDINGS INC.	-0.74%	-0.30%	+43.75%	+32.43%	44.46B
BEONE MEDICINES AG	-1.07%	+4.79%	+10.85%	+91.60%	41.85B
REVOLUTION MEDICINES, INC.	-1.24%	-2.61%	+331.65%	+546.81%	41.34B
CELLTRION, INC.	-0.62%	-0.06%	+10.15%	+46.02%	30.04B
MEDPACE HOLDINGS, INC.	-2.15%	+0.35%	+24.68%	+152.79%	17.59B
ASCENDIS PHARMA A/S	-6.78%	-10.10%	-	-	15.6B
EUROFINS SCIENTIFIC SE	-3.55%	+3.65%	+21.51%	+38.83%	15.69B
TEMPUS AI, INC.	-1.13%	+8.60%	-9.68%	-	13.93B
Average	-1.76%	+2.39%	+44.17%	+134.07%	26.84B
Weighted average by Cap.	-1.38%	+1.88%	+68.25%	+142.34%

	2024	2025
Net sales	195M 1.23M 1.08M 1.01M 927K 1.73M 118M 1.75M 12.18M 4.72M 60.03M 4.62M 4.51M	91.14M 576K 505K 475K 434K 811K 55.14M 817K 5.7M 2.21M 28.11M 2.16M 2.11M
Net income	-236M -1.49M -1.31M -1.23M -1.13M -2.1M -143M -2.12M -14.8M -5.74M -72.92M -5.61M -5.48M	-426M -2.69M -2.36M -2.22M -2.03M -3.79M -258M -3.82M -26.64M -10.33M -131M -10.1M -9.87M
Net Debt	-2.17B -13.73M -12.05M -11.32M -10.35M -19.35M -1.31B -19.49M -136M -52.73M -670M -51.54M -50.41M	-1.83B -11.53M -10.12M -9.51M -8.69M -16.25M -1.1B -16.37M -114M -44.28M -563M -43.29M -42.34M